HOME >> MEDICINE >> NEWS
A leading cause of preventable blindness may be controlled by simple course of oral antibiotic

Treating entire communities with the oral antibiotic azithromycin might effectively control an infection that causes widespread eye disease in developing countries, according to a new study.

The eye disease is trachoma, one of the world's leading causes of preventable blindness. Research results show oral treatment to be markedly better in reducing the number of infections than topical therapy, which uses an ointment form of the antibiotic tetracycline. Public health programs historically used the topical ointment for treatment and control of trachoma.

"We have known for decades that we had the antibiotics to successfully treat this disease when cases developed, but we didn't seem to have the right drug delivery method to control the bug over time. Now we know that we do, and we are very excited at the promise of these results," said Julius Schachter, PhD, professor of laboratory medicine at the University of California San Francisco and lead investigator of the study.

"Although azithromycin costs more than tetracycline ointment, the expense may be offset by the higher costs of distributing and administering multiple doses of the ointment," added Schachter, who also is director of the UCSF Chlamydia Research Laboratory at San Francisco General Hospital Medical Center. Study findings are reported in the August 21st issue of the British medical journal, The Lancet.

Researchers compared the effect of the two antibiotic regimens on infection rates in villages located in trachoma endemic areas where transmission of infection is high. The villages were in the African countries of Egypt, The Gambia, and Tanzania.

Previous studies have shown that topical antibiotics reduced the severity of disease and infection levels for the short-term, but they did not control trachoma levels over the long-term.

Trachoma occurs when the bacterium Chlamydia trachomatis infects the inner eyelid. The disease persists in staggering numbers in developing countr
'"/>

Contact: Rebecca Sladek Nowlis
rsnowlis@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
20-Aug-1999


Page: 1 2 3

Related medicine news :

1. Public morally obliged to take part in scientific research, says leading ethicist
2. New guideline tackles leading cause of mother and child death
3. Breast implant Website launched by leading plastic surgery societies
4. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
5. Government approach to cutting hospital stays may be misleading
6. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
7. Money issues leading cause of holiday stress for Americans
8. Tar measurements on cigarette packets are misleading
9. Researchers discover new clinical syndrome leading to severe osteoarthritis
10. Lung cancer now leading cause of cancer death in women
11. Mechanism leading to life-threatening infection identified by UCSD School of Medicine researchers

Post Your Comments:
(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
Cached News: